Is There Value of Tumor Stromal Infiltrating Lymphocytes for Response Assessment to Chemoradiation in Esophageal Squamous Cell Carcinoma?

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2020 Feb 5

PMID 32016002

Citations 1

Authors

Xin Wang

Wang Jing

Steven H Lin

Affiliations

Soon will be listed here.

Citing Articles

Systemic Immune-Inflammatory Index, Tumor-Infiltrating Lymphocytes, and Clinical Outcomes in Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy.

Yang J, Zheng J, Qiu J, Zhang M, Liu L, Wang Z J Immunol Res. 2023; 2023:4275998.

PMID: 37228442 PMC: 10205413. DOI: 10.1155/2023/4275998.

References

Noordman B, Spaander M, Valkema R, Wijnhoven B, van Berge Henegouwen M, Shapiro J . Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol. 2018; 19(7):965-974. DOI: 10.1016/S1470-2045(18)30201-8. View

Zheng X, Song X, Shao Y, Xu B, Hu W, Zhou Q . Prognostic Role of Tumor-Infiltrating Lymphocytes in Esophagus Cancer: a Meta-Analysis. Cell Physiol Biochem. 2018; 45(2):720-732. DOI: 10.1159/000487164. View

Liu K, Yang K, Wu B, Chen H, Chen X, Chen X . Tumor-Infiltrating Immune Cells Are Associated With Prognosis of Gastric Cancer. Medicine (Baltimore). 2015; 94(39):e1631. PMC: 4616881. DOI: 10.1097/MD.0000000000001631. View

Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z . Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018; 36(27):2796-2803. PMC: 6145832. DOI: 10.1200/JCO.2018.79.1483. View

Miyata H, Tanaka K, Makino T, Yamasaki M, Miyazaki Y, Takahashi T . The Impact of Pathological Tumor Regression and Nodal Status on Survival and Systemic Disease in Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2018; 25(8):2409-2417. DOI: 10.1245/s10434-018-6507-5. View

Zhang H, Tan S, Chen W, Kligerman S, Kim G, DSouza W . Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. Int J Radiat Oncol Biol Phys. 2013; 88(1):195-203. PMC: 3875172. DOI: 10.1016/j.ijrobp.2013.09.037. View

Luen S, Salgado R, Dieci M, Vingiani A, Curigliano G, Gould R . Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol. 2018; 30(2):236-242. DOI: 10.1093/annonc/mdy547. View

Swisher S, Wu Y, Castaneda C, Lyons G, Yang F, Tapia C . Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Ann Surg Oncol. 2016; 23(7):2242-8. DOI: 10.1245/s10434-016-5173-8. View

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

10.

Zingg U, Montani M, Frey D, Dirnhofer S, Esterman A, Went P . Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur J Surg Oncol. 2010; 36(7):670-7. DOI: 10.1016/j.ejso.2010.05.012. View

11.

Fang P, Musall B, Son J, Moreno A, Hobbs B, Carter B . Multimodal Imaging of Pathologic Response to Chemoradiation in Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2018; 102(4):996-1001. PMC: 6119639. DOI: 10.1016/j.ijrobp.2018.02.029. View

12.

Vollenbrock S, Voncken F, van Dieren J, Lambregts D, Maas M, Meijer G . Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer. Br J Surg. 2019; 106(5):596-605. PMC: 6594024. DOI: 10.1002/bjs.11094. View

13.

Wang J, Qin J, Jing S, Liu Q, Cheng Y, Wang Y . Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: Is esophagectomy always necessary? A systematic review and meta-analysis. Thorac Cancer. 2018; 9(12):1638-1647. PMC: 6275815. DOI: 10.1111/1759-7714.12874. View

14.

Mariette C, Dahan L, Mornex F, Maillard E, Thomas P, Meunier B . Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014; 32(23):2416-22. DOI: 10.1200/JCO.2013.53.6532. View

15.

Rawat S, Kumar G, Kakria A, Sharma M, Chauhan D . Chemoradiotherapy in the management of locally advanced squamous cell carcinoma esophagus: is surgical resection required?. J Gastrointest Cancer. 2013; 44(3):277-84. DOI: 10.1007/s12029-013-9477-7. View

16.

Sjoquist K, Burmeister B, Smithers B, Zalcberg J, Simes R, Barbour A . Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12(7):681-92. DOI: 10.1016/S1470-2045(11)70142-5. View

17.

Ochi T, Bianchini G, Ando M, Nozaki F, Kobayashi D, Criscitiello C . Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. Eur J Cancer. 2019; 118:41-48. DOI: 10.1016/j.ejca.2019.05.014. View

18.

Noble F, Mellows T, McCormick Matthews L, Bateman A, Harris S, Underwood T . Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Cancer Immunol Immunother. 2016; 65(6):651-62. PMC: 4880639. DOI: 10.1007/s00262-016-1826-5. View

19.

Qian D, Wang Y, Zhao G, Cao F, Er P, Chen X . Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2019; 105(2):319-328. DOI: 10.1016/j.ijrobp.2019.06.079. View

20.

Tian T, Ruan M, Yang W, Shui R . Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers. Oncotarget. 2016; 7(28):44395-44405. PMC: 5190105. DOI: 10.18632/oncotarget.10054. View